Amarin | AMRN - Actif À Court Terme





Actif À Court Terme Changement Date
AbbVie USD 33.53B 4.47B 2026-03
Alnylam Pharmaceuticals USD 4.62B 400.86M 2026-06
Amarin USD 602.76M 23.26M 2026-06
AstraZeneca USD 27.97B 1.65B 2026-06
BioCryst Pharmaceuticals USD 373.62M 30.72M 2026-03
DBV Technologies USD 201.9M 44.8M 2026-06
GlaxoSmithKline GBP 17.56B 202M 2026-06
Halozyme Therapeutics USD 1B 177.83M 2026-03
Heron Therapeutics USD 228.98M 9.08M 2026-03
Ionis Pharmaceuticals USD 2.49B 446.73M 2026-06
Nektar Therapeutics USD 266.27M 15.09M 2025-12
Neurocrine Biosciences USD 1.64B 798.6M 2026-06
Novartis USD 27.35B 744M 2026-06